Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus Anlotinib Maintenance in ES-SCLC
NCT06441344Phase 3Not yet recruiting
- Sponsor
- Taizhou Hospital of Zhejiang Province
- Start
- Jul 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of anlotinib in small cell lung cancer (SCLC), sponsored by Taizhou Hospital of Zhejiang Province. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06441344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441344.